Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD4785 |
| Synonyms | |
| Therapy Description |
AZD4785 is an antisense oligonucleotide targeting KRAS that results in the depletion of KRAS mRNA and protein, therefore leads to inhibition of tumor cell growth (PMID: 28615361). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD4785 | AZD-4785|AZD 785 | Antisense Therapy 14 KRAS Inhibitor 30 | AZD4785 is an antisense oligonucleotide targeting KRAS that results in the depletion of KRAS mRNA and protein, therefore leads to inhibition of tumor cell growth (PMID: 28615361). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03101839 | Phase I | AZD4785 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |